Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Ironwood Pharmaceuticals, Inc. (IRWD) - free report >>
AbbVie Inc. (ABBV) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ironwood Pharmaceuticals, Inc. (IRWD) - free report >>
AbbVie Inc. (ABBV) - free report >>
Image: Bigstock
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA
Shares of Ardelyx, Inc. (ARDX - Free Report) plummeted 73.9% following negative regulatory update related to its new drug application (“NDA”) seeking approval for lead pipeline candidate, tenapanor, as a treatment for hyperphosphatemia, an elevated level of serum phosphate in the blood, in patients with chronic kidney disease on dialysis.
The company announced that the FDA identified deficiencies in the NDA, which prevent discussion related to labeling and post-marketing requirements/commitments currently. Although the FDA did not provide specific details regarding the deficiencies, it noted that the size of the treatment effect and its clinical relevance was a key issue. Moreover, the FDA denied a request for a meeting made by the company to discuss the deficiencies.
The FDA also stated that the notification about deficiencies does not reflect its final decision related to the NDA.
We note that Ardelyx submitted the NDA supported by data from three successful pivotal studies. The company also had a discussion related to labeling with the FDA in April. The unexpected deficiency notification from the FDA significantly impacted investors’ sentiments. However, the FDA had extended the review period for tenapanor NDA in April by three months.
Shares of Ardelyx have declined 68.9% so far this year compared with the industry’s decrease of 11.9%.
Image Source: Zacks Investment Research
The company’s tenapanor is already approved as Ibsrela for treating irritable bowel syndrome with constipation (IBS-C) in adults.
However, we note that Ironwood Pharmaceuticals (IRWD - Free Report) /AbbVie’s (ABBV - Free Report) Linzess holds a strong position in the IBS-C segment. Bausch Health (BHC - Free Report) has an IBS-C drug, Trulance, in its marketed portfolio. These drugs pose competition to Ibsrela.
Ardelyx is also developing another pipeline candidate, RDX013, as a treatment for hyperkalemia — a condition of elevated level of potassium in the blood. The company has an ongoing discovery program for a bicarbonate exchange inhibitor for the treatment of metabolic acidosis.
Ardelyx, Inc. Price
Ardelyx, Inc. price | Ardelyx, Inc. Quote
Zacks Rank
Ardelyx currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.